t is well established that lipid-lowering therapy with statins has an effect on the primary and secondary prevention of ischemic coronary events that is mediated by a decrease in low-density lipoprotein cholesterol (LDL-C). 1- 3 Recent trials have further demonstrated reduced progression of atherosclerotic plaques with intensive statin therapy. 4, 5 These trials showed that the changes in plaque volume and LDL-C decrease are positively correlated and an aggressive lipid-modulating strategy can reverse the progress of atherosclerotic disease. Plaque stabilization achieved by modifying plaque composition with statin therapy has also been reported and the degree of change in plaque composition positively correlated with changes in LDL-C. 6,7 On the basis of these findings, LDL-C levels <100 mg/dl are recommended for the secondary prevention of myocardial infarction by the American Heart Association and also by the Japanese Circulation Society.
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In this issue of the Journal, Kovarnik et al report on the role of ezetimibe in atherosclerosis regression and alternation of atherosclerotic plaque composition. 8 In their study, 89 patients with stable angina were randomized in a 1:1 ratio to the aggressive group (dual hypolipidemic therapy: atorvastatin 80 mg + ezetimibe 10 mg) or standard dose of statin therapy group and analyzed at base line and 12-month follow-up. Volumetric intravascular ultrasound (IVUS) analysis was performed to evaluate atheroma volume. Plaque composition was assessed by virtual histology IVUS (VH-IVUS), in which spectral analysis of radiofrequency ultrasound backscatter signals from the IVUS images were evaluated to define fibrous area, fibro-fatty area, dense calcific area, and necrotic core area within the plaque. The authors found that the percent atheroma volume (PAV) was significantly decreased (−0.4%) in the aggressive group compared with the standard dose group. The change in PAV correlated with the percent change in LDL-C at follow-up. However, no differences were observed in plaque compositional changes between the aggressive and standard dose groups as measured by VH-IVUS. Fibrous and fibro-fatty tissues decreased and necrotic core and calcification increased in both groups. To identify the predictors of plaque regression, multivariate regression analysis was performed. Although a follow-up LDL-C level <2 mmol/L was found to be an independent predictor of plaque regression, aggressive hypolipidemic treatment (atorvastatin 80 mg + ezetimibe 10 mg) was not related to plaque regression. On the basis of these findings, the authors conclude that atherosclerosis regression depends more on achieving the target LDL-C level than on treatment type.
Although this conclusion may be compatible with previous studies, several issues must be considered to put these observations into perspective. First of all, statins have been recognized as having anti-inflammatory and antioxidant properties, and it has been suggested that these so-called 'pleiotropic' effects may account for some of the benefits of statins beyond LDL-C lowering alone. 9-11 Furthermore, in the JUPITER trial of patients with normal LDL-C levels, but increased levels of high-sensitivity C-reactive protein (hs-CRP), rosuvastatin significantly reduced the incidence of major cardiac events. 12 In addition, a recently published pooled analysis revealed that diabetic subjects continued to demonstrate greater increases in atheroma volume, but both intensive lowering of LDL-C and intensive lowering of CRP had a favorable impact on plaque progression. 13 Another observational study showed that improving control of glycemic, lipid, and inflammatory markers with the peroxisome proliferator-activated receptor-gamma agonist, pioglitazone, slows progression of carotid intimal medial thickness without decreasing LDL-C level. 14 These findings suggest that treatment strategies guided by LDL-C level might not always be sufficient to achieve regression or stabilization of established atherosclerosis. Finally, it must be noted that Kovarnik et al compared patients treated with atorvastatin 80 mg and ezetimibe 10 mg with patients treated with standard doses of statins (atorvastatin 10 mg). Because of the differences in statin doses between the 2 groups, it might be under-powered to evaluate the precise role of ezetimibe in atherosclerosis regression and alteration of atherosclerotic plaque composition.
Notwithstanding these limitations, their report provides potentially interesting information that needs to be validated prospectively in larger cohorts of patients. Several questions remain: How to decrease? How much decrease? Which is the more justifiable approach to decreasing LDL-C in established atherosclerosis? What is the essential significance of LDL-C lowering in plaque regression or stabilization? Furthermore, it remains possible that focusing on LDL-C alone is insufficient. The point in question remains uncertain and warrants further investigation.
